The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The partnership aims to improve cancer molecular profiling by combining Horizon's HDx reference standards with Sophia's artificial intelligence solution.
The companies will combine their respective technologies to provide an integrated analytical and next-generation sequencing sample preparation offering for cancer research.
The co-marketing arrangement will initially cover hospitals and laboratories in Europe, the Middle East, and Africa.
Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.
Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.
The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.
The partners will work on alternatives to current data protection methods which they say make healthcare data unusable for analysis, diagnostics.
The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.
The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.